肝病学的突破

StephenW

肝病学的突破

    诺拉 A.特罗
    让-弗朗索瓦·杜福尔
    罗伯特·F·施瓦贝
    黄伟新

DOI：https://doi.org/10.1016/j.jhep.2022.04.001

   
在医学界，没有什么比通过研究努力积累知识和随之而来的临床实践转变更令人满意的了。我们这一代的许多同事都记得我们努力照顾慢性病毒性肝炎患者的日子，提供的治疗方法很少，随着时间的推移，一些患者的病情不可避免地恶化。快进到现在，通过 8 至 12 周的直接抗病毒药物根除慢性丙型肝炎感染，并且基本上 100% 接受恩替卡韦或替诺福韦治疗慢性乙型肝炎的患者实现了持续的病毒抑制。此外，这些高效的治疗方法已转化为肝脏相关发病率和死亡率的显着降低。肝移植曾经被视为激进且有风险，现在已成为终末期肝病患者的护理标准，并且与长期存活率高相关。我们确实是几十年创新突破的受益者

StephenW

Breakthroughs in hepatology

    Norah A. Terrault
    Jean-François Dufour
    Robert F. Schwabe
    Vincent Wai-Sun Wong

DOI:https://doi.org/10.1016/j.jhep.2022.04.001

   
In medicine, nothing is more satisfying than witnessing the accumulation of knowledge through research efforts and the transformation of clinical practice that follows. Many colleagues from our generation remember the days when we struggled to care for patients with chronic viral hepatitis, with few therapies to offer and the inevitable deterioration in some patients over time. Fast forward to the present where chronic hepatitis C infection is eradicated with 8 to 12 weeks of direct-acting antivirals and essentially 100% of patients treated with entecavir or tenofovir for chronic hepatitis B achieve sustained viral suppression. Moreover, these highly effective treatments have translated into meaningful reductions in liver-related morbidity and mortality. Liver transplantation, once viewed as radical and risky, is now a standard of care in patients with end-stage liver disease and is associated with excellent long-term survival. We are indeed the beneficiaries of decades of innovation and breakthroughs

乙肝人1949

没有看懂